Literature DB >> 30730305

uPAR isoform 2 forms a dimer and induces severe kidney disease in mice.

Changli Wei1, Jing Li1, Brian D Adair2, Ke Zhu1, Jian Cai3, Michael Merchant3, Beata Samelko1, Zhongji Liao4, Kwi Hye Koh1, Nicholas J Tardi1, Ranadheer R Dande1, Shuangxin Liu1, Jianchao Ma1, Salvatore Dibartolo1, Stefan Hägele1, Vasil Peev1, Salim S Hayek5, David J Cimbaluk6, Melissa Tracy1, Jon Klein3, Sanja Sever2, Sanford J Shattil4, M Amin Arnaout2, Jochen Reiser1.   

Abstract

Soluble urokinase plasminogen activator receptor (suPAR) is an immune-derived circulating signaling molecule that has been implicated in chronic kidney disease, such as focal segmental glomerulosclerosis (FSGS). Typically, native uPAR (isoform 1) translates to a 3-domain protein capable of binding and activating integrins, yet the function of additional isoforms generated by alternative splicing is unknown. Here, we characterized mouse uPAR isoform 2 (msuPAR2), encoding domain I and nearly one-half of domain II, as a dimer in solution, as revealed by 3D electron microscopy structural analysis. In vivo, msuPAR2 transgenic mice exhibited signs of severe renal disease characteristic of FSGS with proteinuria, loss of kidney function, and glomerulosclerosis. Sequencing of the glomerular RNAs from msuPAR2-Tg mice revealed a differentially expressed gene signature that includes upregulation of the suPAR receptor Itgb3, encoding β3 integrin. Crossing msuPAR2-transgenic mice with 3 different integrin β3 deficiency models rescued msuPAR2-mediated kidney function. Further analyses indicated a central role for β3 integrin and c-Src in msuPAR2 signaling and in human FSGS kidney biopsies. Administration of Src inhibitors reduced proteinuria in msuPAR2-transgenic mice. In conclusion, msuPAR2 may play an important role in certain forms of scarring kidney disease.

Entities:  

Keywords:  Chronic kidney disease; Integrins; Nephrology; Protein kinases

Mesh:

Substances:

Year:  2019        PMID: 30730305      PMCID: PMC6486353          DOI: 10.1172/JCI124793

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  33 in total

1.  DAVID: Database for Annotation, Visualization, and Integrated Discovery.

Authors:  Glynn Dennis; Brad T Sherman; Douglas A Hosack; Jun Yang; Wei Gao; H Clifford Lane; Richard A Lempicki
Journal:  Genome Biol       Date:  2003-04-03       Impact factor: 13.583

2.  More powerful procedures for multiple significance testing.

Authors:  Y Hochberg; Y Benjamini
Journal:  Stat Med       Date:  1990-07       Impact factor: 2.373

3.  Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice.

Authors:  Dominique Cathelin; Sandrine Placier; Michael Ploug; Marie-Christine Verpont; Sophie Vandermeersch; Yosu Luque; Alexandre Hertig; Eric Rondeau; Laurent Mesnard
Journal:  J Am Soc Nephrol       Date:  2014-05-01       Impact factor: 10.121

4.  Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties.

Authors:  Simon C Satchell; Karen L Anderson; Peter W Mathieson
Journal:  J Am Soc Nephrol       Date:  2004-03       Impact factor: 10.121

5.  An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator.

Authors:  C Pyke; J Eriksen; H Solberg; B S Nielsen; P Kristensen; L R Lund; K Danø
Journal:  FEBS Lett       Date:  1993-07-12       Impact factor: 4.124

6.  Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation.

Authors:  Cole Trapnell; Brian A Williams; Geo Pertea; Ali Mortazavi; Gordon Kwan; Marijke J van Baren; Steven L Salzberg; Barbara J Wold; Lior Pachter
Journal:  Nat Biotechnol       Date:  2010-05-02       Impact factor: 54.908

7.  Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract.

Authors:  P Kristensen; J Eriksen; F Blasi; K Danø
Journal:  J Cell Biol       Date:  1991-12       Impact factor: 10.539

8.  Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease.

Authors:  Eunsil Hahm; Changli Wei; Isabel Fernandez; Jing Li; Nicholas J Tardi; Melissa Tracy; Shikha Wadhwani; Yanxia Cao; Vasil Peev; Andrew Zloza; Jevgenijs Lusciks; Salim S Hayek; Christopher O'Connor; Markus Bitzer; Vineet Gupta; Sanja Sever; David B Sykes; David T Scadden; Jochen Reiser
Journal:  Nat Med       Date:  2016-12-12       Impact factor: 53.440

9.  The selectivity of protein kinase inhibitors: a further update.

Authors:  Jenny Bain; Lorna Plater; Matt Elliott; Natalia Shpiro; C James Hastie; Hilary McLauchlan; Iva Klevernic; J Simon C Arthur; Dario R Alessi; Philip Cohen
Journal:  Biochem J       Date:  2007-12-15       Impact factor: 3.857

10.  TopHat: discovering splice junctions with RNA-Seq.

Authors:  Cole Trapnell; Lior Pachter; Steven L Salzberg
Journal:  Bioinformatics       Date:  2009-03-16       Impact factor: 6.937

View more
  23 in total

1.  c-Src is in the effector pathway linking uPAR and podocyte injury.

Authors:  Jeffrey B Kopp; Jurgen Heymann
Journal:  J Clin Invest       Date:  2019-04-02       Impact factor: 14.808

2.  Plasma Soluble Urokinase Plasminogen Activator Receptor (suPAR) and CKD Progression in Children.

Authors:  Darcy K Weidemann; Alison G Abraham; Jennifer L Roem; Susan L Furth; Bradley A Warady
Journal:  Am J Kidney Dis       Date:  2020-01-24       Impact factor: 8.860

3.  Novel Pure αVβ3 Integrin Antagonists That Do Not Induce Receptor Extension, Prime the Receptor, or Enhance Angiogenesis at Low Concentrations.

Authors:  Jihong Li; Yoshiyuki Fukase; Yi Shang; Wei Zou; José M Muñoz-Félix; Lorena Buitrago; Johannes van Agthoven; Yixiao Zhang; Ryoma Hara; Yuta Tanaka; Rei Okamoto; Takeshi Yasui; Takashi Nakahata; Toshihiro Imaeda; Kazuyoshi Aso; Yuchen Zhou; Charles Locuson; Dragana Nesic; Mark Duggan; Junichi Takagi; Roger D Vaughan; Thomas Walz; Kairbaan Hodivala-Dilke; Steven L Teitelbaum; M Amin Arnaout; Marta Filizola; Michael A Foley; Barry S Coller
Journal:  ACS Pharmacol Transl Sci       Date:  2019-08-02

Review 4.  Soluble Urokinase Receptor and Liver Disease.

Authors:  Changli Wei; Ke Zhu; Jochen Reiser
Journal:  Clin Liver Dis (Hoboken)       Date:  2019-12-20

5.  Podocyte Integrin-β 3 and Activated Protein C Coordinately Restrict RhoA Signaling and Ameliorate Diabetic Nephropathy.

Authors:  Thati Madhusudhan; Sanchita Ghosh; Hongjie Wang; Wei Dong; Dheerendra Gupta; Ahmed Elwakiel; Stoyan Stoyanov; Moh'd Mohanad Al-Dabet; Shruthi Krishnan; Ronald Biemann; Sumra Nazir; Silke Zimmermann; Akash Mathew; Ihsan Gadi; Rajiv Rana; Jinyang Zeng-Brouwers; Marcus J Moeller; Liliana Schaefer; Charles T Esmon; Shrey Kohli; Jochen Reiser; Alireza R Rezaie; Wolfram Ruf; Berend Isermann
Journal:  J Am Soc Nephrol       Date:  2020-07-24       Impact factor: 10.121

6.  Soluble Urokinase Receptor and Acute Kidney Injury.

Authors:  Salim S Hayek; David E Leaf; Ayman Samman Tahhan; Mohamad Raad; Shreyak Sharma; Sushrut S Waikar; Sanja Sever; Alex Camacho; Xuexiang Wang; Ranadheer R Dande; Nasrien E Ibrahim; Rebecca M Baron; Mehmet M Altintas; Changli Wei; David Sheikh-Hamad; Jenny S-C Pan; Michael W Holliday; James L Januzzi; Steven D Weisbord; Arshed A Quyyumi; Jochen Reiser
Journal:  N Engl J Med       Date:  2020-01-30       Impact factor: 91.245

7.  Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI.

Authors:  Tariq U Azam; Husam R Shadid; Pennelope Blakely; Patrick O'Hayer; Hanna Berlin; Michael Pan; Peiyao Zhao; Lili Zhao; Subramaniam Pennathur; Rodica Pop-Busui; Izzet Altintas; Jens Tingleff; Marius A Stauning; Ove Andersen; Maria-Evangelia Adami; Nicky Solomonidi; Maria Tsilika; Pinkus Tober-Lau; Eleni Arnaoutoglou; Verena Keitel; Frank Tacke; Athanasios Chalkias; Sven H Loosen; Evangelos J Giamarellos-Bourboulis; Jesper Eugen-Olsen; Jochen Reiser; Salim S Hayek
Journal:  J Am Soc Nephrol       Date:  2020-09-22       Impact factor: 10.121

Review 8.  Biomarkers in pediatric glomerulonephritis and nephrotic syndrome.

Authors:  Gabriel Cara-Fuentes; William E Smoyer
Journal:  Pediatr Nephrol       Date:  2021-01-03       Impact factor: 3.714

Review 9.  The glomerular filtration barrier: a structural target for novel kidney therapies.

Authors:  Ilse S Daehn; Jeremy S Duffield
Journal:  Nat Rev Drug Discov       Date:  2021-07-14       Impact factor: 84.694

10.  RAGE and αVβ3-integrin are essential for suPAR signaling in podocytes.

Authors:  Eun Young Kim; Stuart E Dryer
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2021-06-22       Impact factor: 6.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.